MDT

99.9

+1.76%↑

A

138.14

+1.9%↑

VEEV

218.54

+0.71%↑

HQY

84.81

+0.3%↑

NEOG

9.68

+4.31%↑

MDT

99.9

+1.76%↑

A

138.14

+1.9%↑

VEEV

218.54

+0.71%↑

HQY

84.81

+0.3%↑

NEOG

9.68

+4.31%↑

MDT

99.9

+1.76%↑

A

138.14

+1.9%↑

VEEV

218.54

+0.71%↑

HQY

84.81

+0.3%↑

NEOG

9.68

+4.31%↑

MDT

99.9

+1.76%↑

A

138.14

+1.9%↑

VEEV

218.54

+0.71%↑

HQY

84.81

+0.3%↑

NEOG

9.68

+4.31%↑

MDT

99.9

+1.76%↑

A

138.14

+1.9%↑

VEEV

218.54

+0.71%↑

HQY

84.81

+0.3%↑

NEOG

9.68

+4.31%↑

Search

CareDx Inc

Abrir

SetorSaúde

20.45 2.82

Visão Geral

Variação de preço das ações

24h

Atual

Mín

19.8

Máximo

20.62

Indicadores-chave

By Trading Economics

Rendimento

10M

1.7M

Vendas

13M

100M

P/E

Médio do Setor

15.633

89.037

Margem de lucro

1.674

Funcionários

644

EBITDA

11M

6.8M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-10.04% downside

Dividendos

By Dow Jones

Próximos Ganhos

25 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

279M

1.1B

Abertura anterior

17.63

Fecho anterior

20.45

Sentimento de Notícias

By Acuity

34%

66%

76 / 361 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

CareDx Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de jan. de 2026, 23:43 UTC

Conversa de Mercado

Gold Consolidates; May Face Technical Correction -- Market Talk

20 de jan. de 2026, 23:42 UTC

Conversa de Mercado

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 de jan. de 2026, 23:41 UTC

Ganhos

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 de jan. de 2026, 23:29 UTC

Conversa de Mercado

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 de jan. de 2026, 23:26 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de jan. de 2026, 23:26 UTC

Conversa de Mercado

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 de jan. de 2026, 22:45 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 de jan. de 2026, 22:45 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 de jan. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 de jan. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 de jan. de 2026, 22:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 de jan. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 de jan. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 de jan. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 de jan. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 de jan. de 2026, 22:18 UTC

Ganhos

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 de jan. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 de jan. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 de jan. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 de jan. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 de jan. de 2026, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 de jan. de 2026, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 de jan. de 2026, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 de jan. de 2026, 22:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 de jan. de 2026, 22:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 de jan. de 2026, 22:06 UTC

Ganhos

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 de jan. de 2026, 22:00 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

ESG Roundup: Market Talk

20 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

Comparação entre Pares

Variação de preço

CareDx Inc Previsão

Preço-alvo

By TipRanks

-10.04% parte inferior

Previsão para 12 meses

Média 18 USD  -10.04%

Máximo 18 USD

Mínimo 18 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para CareDx Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

1

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

14.77 / 18.49Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

76 / 361 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat